Kineta, Inc.

Seattle, WA 98109

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $5.62MM
Active Awards 1 valued at $746K
First Award Date 09/05/08
Most Recent Award Date 06/01/17

Key Personnel

Last Name Name Awards Contact
Iadonato Shawn Patrick Iadonato 7
Gale Michael J Gale 5
BEDARD KRISTIN M BEDARD 2
PROBST PETER PROBST 1
STEVENS ANNE MARGUERITE STEVENS 1

10 Awards Won

Phase 2 SBIR Active

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 06/01/17 - 05/31/18

? DESCRIPTION (provided by applicant): Kineta has discovered a novel class of broad spectrum small molecule antivirals that function through a host directed mechanism. These compounds have demonstrated an innovative mechanism of action and target several high priority pathogens that are commercially valuable. The lead chromenone-based candid...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 08/10/16 - 07/31/17

? DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with poorly understood etiology and pathogenesis and for which adequate treatment options are limited. Although dysregulated production of autoantibodies and immune complex deposition are considered hallmarks of SLE, considerab...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 06/22/16 - 05/31/17

? DESCRIPTION (provided by applicant): Kineta has discovered a novel class of broad spectrum small molecule antivirals that function through a host directed mechanism. These compounds have demonstrated an innovative mechanism of action and target several high priority pathogens that are commercially valuable. The lead chromenone-based candidat...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/01/13 - 06/30/14

DESCRIPTION (provided by applicant): Through Phase I studies, we have identified five lead small molecule compounds with drug-like properties that activate innate immune response pathways and inhibit the replication of RNA viruses such as hepatitis C virus (HCV), influenza virus (FLU), and West Nile virus (WNV). There is a tremendous commercia...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/01/12 - 06/30/13

DESCRIPTION (provided by applicant): Through Phase I studies, we have identified five lead small molecule compounds with drug-like properties that activate innate immune response pathways and inhibit the replication of RNA viruses such as hepatitis C virus (HCV), influenza virus (FLU), and West Nile virus (WNV). There is a tremendous commercia...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/15/11 - 06/30/12

DESCRIPTION (provided by applicant): Through Phase I studies, we have identified five lead small molecule compounds with drug-like properties that activate innate immune response pathways and inhibit the replication of RNA viruses such as hepatitis C virus (HCV), influenza virus (FLU), and West Nile virus (WNV). There is a tremendous commercia...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 04/01/11 - 12/31/12

Multiple sclerosis (MS) affects approximately 400,000 Americans and constitutes a progressive, disabling disease for which current therapies are inadequate. This application describes the nonclinical development of ShK-186, a novel Kv1.3 potassium channel inhibitor that targets the effector memory T cell (TEM) population in MS. TEM cells play a ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 04/01/10 - 03/31/11

DESCRIPTION (provided by applicant): Multiple sclerosis (MS) affects approximately 400,000 Americans and constitutes a progressive, disabling disease for which current therapies are inadequate. This application describes the nonclinical development of ShK-186, a novel Kv1.3 potassium channel inhibitor that targets the effector memory T cell (TEM...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 09/01/09 - 08/31/10

DESCRIPTION (provided by applicant): There is a tremendous commercial demand for new antiviral products with novel mechanisms of action and which target a broad spectrum of viruses. Most previous and ongoing pharmaceutical development programs involve screening for inhibitors of essential virus enzymes with comparatively little investment in dru...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 09/05/08 - 08/31/09

DESCRIPTION (provided by applicant): There is a tremendous commercial demand for new antiviral products with novel mechanisms of action and which target a broad spectrum of viruses. Most previous and ongoing pharmaceutical development programs involve screening for inhibitors of essential virus enzymes with comparatively little investment in dru...

Load More